BCL2 and lymphoma: In the later stages of treatment, (-due to poor response to previous lines of therapy-), we decided to treat the patient based on the results of a retrospective analysis by Richard-Carpentier et al., in which venetoclax, a selective BCL2 inhibitor, was used in combination with chemotherapy for lymphoma (R/R T-ALL).